Forster Eliot
SEC insider (Form 3/4/5 filer). CIK 0001831558. Director at Protalix BioTherapeutics, Inc. (PLX) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Sep 3, 2026. Located in CARMIEL.
Companies Forster Eliot has filed insider reports for
- Protalix BioTherapeutics, Inc. (PLX): Director
- Immatics N.V. (IMTX): Director
Forster Eliot
CIK: 0001831558
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
AwardDirectStock Options (Right to Buy)
17K shares- - Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
AwardDirectRestricted Stock Units
8.5K shares- - Jun 16, 2026IMTX
Immatics N.V.
AwardDirectStock Option (Right to Buy)
48K shares- - Sep 3, 2025PLX
Protalix BioTherapeutics, Inc.
AwardIndirect7.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 3, 2026 |  PLX Protalix BioTherapeutics, Inc. | Award Stock Options (Right to Buy) | 17,000 | - | - | Direct |
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | Award Restricted Stock Units | 8,500 | - | - | Direct |
| Jun 16, 2026 |  IMTX Immatics N.V. | Award Stock Option (Right to Buy) | 48,000 | - | - | Direct |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | Award | 7,500 | - | - | Indirect |
1-4 of 4 transactions